← All trials
NCT06934655
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2025
- Primary completion
- Nov 1, 2030
- Completion date
- Nov 1, 2033
- First posted
- Apr 18, 2025
- Last posted
- Apr 18, 2025
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Children's Hospital Los AngelesLead sponsor
- Children's Hospital Los AngelesSponsor investigator
- Children's Hospital Los AngelesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.